Market Closed -
London S.E.
09:05:27 02/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.567
GBX
|
+0.13%
|
|
-3.81%
|
-31.87%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
8.901
|
7.564
|
7.044
|
41.85
|
18.37
|
12.98
|
Enterprise Value (EV)
1 |
7.024
|
6.974
|
7.803
|
41.66
|
11.54
|
13.87
|
P/E ratio
|
-2.76
x
|
-5.12
x
|
-4.85
x
|
-19.2
x
|
-2.85
x
|
-3.26
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-8.39
x
|
-4.46
x
|
-4.79
x
|
-20
x
|
-4.42
x
|
-3.55
x
|
EV / FCF
|
-34
x
|
-8.13
x
|
-9.09
x
|
-37.9
x
|
-3.72
x
|
-5.79
x
|
FCF Yield
|
-2.94%
|
-12.3%
|
-11%
|
-2.64%
|
-26.9%
|
-17.3%
|
Price to Book
|
4.22
x
|
7.89
x
|
-20.3
x
|
47
x
|
2.24
x
|
3.96
x
|
Nbr of stocks (in thousands)
|
3,56,043
|
3,60,176
|
3,61,243
|
4,33,636
|
9,79,749
|
9,79,749
|
Reference price
2 |
0.0250
|
0.0210
|
0.0195
|
0.0965
|
0.0188
|
0.0132
|
Announcement Date
|
13/06/18
|
28/05/19
|
13/05/20
|
28/05/21
|
08/06/22
|
02/06/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-0.8371
|
-1.563
|
-1.627
|
-2.081
|
-2.613
|
-3.908
|
EBIT
1 |
-0.8707
|
-1.615
|
-1.684
|
-2.15
|
-2.703
|
-3.998
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.411
|
-1.521
|
-1.488
|
-2.095
|
-5.108
|
-3.987
|
Net income
1 |
-2.362
|
-1.478
|
-1.451
|
-2.082
|
-5.099
|
-3.979
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.009073
|
-0.004102
|
-0.004021
|
-0.005019
|
-0.006588
|
-0.004061
|
Free Cash Flow
1 |
-0.2068
|
-0.8577
|
-0.8581
|
-1.098
|
-3.106
|
-2.395
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/06/18
|
28/05/19
|
13/05/20
|
28/05/21
|
08/06/22
|
02/06/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
0.76
|
-
|
-
|
0.89
|
Net Cash position
1 |
1.88
|
0.59
|
-
|
0.18
|
6.83
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-0.4661
x
|
-
|
-
|
-0.2278
x
|
Free Cash Flow
1 |
-0.21
|
-0.86
|
-0.86
|
-1.1
|
-3.11
|
-2.39
|
ROE (net income / shareholders' equity)
|
-187%
|
-95.6%
|
-476%
|
-796%
|
-113%
|
-69.9%
|
ROA (Net income/ Total Assets)
|
-35.1%
|
-43%
|
-62.9%
|
-72.4%
|
-30.2%
|
-32%
|
Assets
1 |
6.731
|
3.436
|
2.308
|
2.877
|
16.88
|
12.43
|
Book Value Per Share
2 |
0.0100
|
0
|
-0
|
0
|
0.0100
|
0
|
Cash Flow per Share
2 |
0.0100
|
0
|
0
|
0
|
0.0100
|
0
|
Capex
1 |
0.06
|
0.02
|
0.01
|
0.17
|
0.64
|
0.43
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/06/18
|
28/05/19
|
13/05/20
|
28/05/21
|
08/06/22
|
02/06/23
|
|
1st Jan change
|
Capi.
|
---|
| -31.87% | 26.23M | | -1.65% | 104B | | +6.75% | 97.47B | | +5.71% | 22.25B | | -12.60% | 21.68B | | -9.70% | 18.2B | | -39.98% | 17.02B | | -10.17% | 16.36B | | +6.12% | 14.39B | | +35.47% | 12.37B |
Bio Therapeutic Drugs
|